Scholarlink

<p>Chronic and recalcitrant dermatophytosis has become an increasing therapeutic challenge, particularly in India, where widespread antifungal misuse and environmental factors contribute to persistent infections. This study investigated the clinical patterns, antifungal susceptibility, and molecular mechanisms underlying terbinafine resistance in patients with tinea corporis and tinea cruris. A total of 105 clinically diagnosed and KOH-positive patients were enrolled. The majority were male (60%) with a mean age of 34 years and an average disease duration of 13 months. Most cases involved multiple sites, with the groin, thighs, and buttocks most frequently affected. Phenotypic and molecular identification revealed <i>Trichophyton mentagrophytes</i>/<i>interdigitale</i> complex (Tm/TiC) as the predominant pathogen (97%), followed by rare isolates of <i>Trichophyton rubrum</i> (2%) and <i>Trichophyton indotineae</i> (1%). Antifungal susceptibility testing (CLSI M38-A2) showed high MIC values for fluconazole (MIC₅₀/₉₀: 64&#xa0;µg/ml), terbinafine (MIC₅₀: 0.5&#xa0;µg/ml, MIC₉₀: 16&#xa0;µg/ml), and griseofulvin (MIC₅₀: 2&#xa0;µg/ml, MIC₉₀: 8&#xa0;µg/ml), while itraconazole exhibited the best in vitro activity (MIC₅₀: 0.25&#xa0;µg/ml, MIC₉₀: 0.5&#xa0;µg/ml). Notably, 33% of isolates demonstrated high terbinafine MICs (≥ 1&#xa0;µg/ml). SQLE gene sequencing identified mutations, particularly F397L, strongly associated with elevated terbinafine MICs and prior drug exposure. These findings highlight the alarming rise of terbinafine resistance among dermatophytes and underscore the role of inappropriate antifungal use in driving resistance. Regular antifungal susceptibility testing, careful drug selection based on prior exposure, and strict patient compliance are essential for improving outcomes. Until clinical breakpoints are established, treatment should be continued until both clinical and mycological cure are achieved.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

In Vitro Terbinafine Response and Minimum Inhibitory Concentration–Squalene Epoxidase Mutation Correlation in Tinea Cruris and Corporis: A Cross-Sectional Study

  • 期刊论文

  • 发表日期：

    2026年5月2日

查看全文
  • Anita Kumari,
  • Shukla Das,
  • Praveen Kumar Singh,
  • Gargi Rai,
  • Swati Sharma,
  • Bineeta Kashyap,
  • Deepika Pandhi,
  • Arshad Jawed,
  • Sajad Ahmad Dar

摘要

Chronic and recalcitrant dermatophytosis has become an increasing therapeutic challenge, particularly in India, where widespread antifungal misuse and environmental factors contribute to persistent infections. This study investigated the clinical patterns, antifungal susceptibility, and molecular mechanisms underlying terbinafine resistance in patients with tinea corporis and tinea cruris. A total of 105 clinically diagnosed and KOH-positive patients were enrolled. The majority were male (60%) with a mean age of 34 years and an average disease duration of 13 months. Most cases involved multiple sites, with the groin, thighs, and buttocks most frequently affected. Phenotypic and molecular identification revealed Trichophyton mentagrophytes/interdigitale complex (Tm/TiC) as the predominant pathogen (97%), followed by rare isolates of Trichophyton rubrum (2%) and Trichophyton indotineae (1%). Antifungal susceptibility testing (CLSI M38-A2) showed high MIC values for fluconazole (MIC₅₀/₉₀: 64 µg/ml), terbinafine (MIC₅₀: 0.5 µg/ml, MIC₉₀: 16 µg/ml), and griseofulvin (MIC₅₀: 2 µg/ml, MIC₉₀: 8 µg/ml), while itraconazole exhibited the best in vitro activity (MIC₅₀: 0.25 µg/ml, MIC₉₀: 0.5 µg/ml). Notably, 33% of isolates demonstrated high terbinafine MICs (≥ 1 µg/ml). SQLE gene sequencing identified mutations, particularly F397L, strongly associated with elevated terbinafine MICs and prior drug exposure. These findings highlight the alarming rise of terbinafine resistance among dermatophytes and underscore the role of inappropriate antifungal use in driving resistance. Regular antifungal susceptibility testing, careful drug selection based on prior exposure, and strict patient compliance are essential for improving outcomes. Until clinical breakpoints are established, treatment should be continued until both clinical and mycological cure are achieved.